Bremelanotide vs Omentin-1
Head-to-head comparison of Bremelanotide (Bremelanotide (PT-141), cyclic melanocortin receptor agonist) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Bremelanotide | Omentin-1 |
|---|---|---|
| Category | Sexual Health | Diabetes & Metabolic |
| Full Name | Bremelanotide (PT-141), cyclic melanocortin receptor agonist | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 1025.2 Da | ~35 kDa |
| Half-Life | about 2.7 h | hours |
| Amino Acids | 7 | 313 |
| Typical Dose | 1.75 mg | No approved human dose; research use only |
| Route | Subcutaneous | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 200 | 82 |
| Research Status | Clinical | Pre-clinical |
Bremelanotide Benefits
- ✓increases sexual desire
- ✓supports arousal
- ✓may improve erectile response
- ✓on-demand use
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Bremelanotide Dosing
1.75 mg subcutaneous PRN|administer about 45 minutes before activity|max 1 dose per 24 hours
Omentin-1 Dosing
not established|not established
Bremelanotide Side Effects
- ⚠nausea
- ⚠flushing
- ⚠headache
- ⚠transient blood pressure increase
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
Bremelanotide
Human studies and approval data support meaningful effects on sexual desire in women, with a central mechanism involving melanocortin signaling. It is one of the most clinically relevant peptides in this category and is commonly used as the reference compound for PT-141-type research.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.